- Home
- SAGE vs ESPR Comparison
SAGE vs ESPR Comparison
Compare SAGE & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- ESPR
- Stock Information
- Founded
- SAGE 2010
- ESPR 2008
- Country
- SAGE United States
- ESPR United States
- Employees
- SAGE N/A
- ESPR N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- SAGE Health Care
- ESPR Health Care
- Exchange
- SAGE Nasdaq
- ESPR Nasdaq
- Market Cap
- SAGE 462.2M
- ESPR 456.6M
- IPO Year
- SAGE 2014
- ESPR 2013
- Fundamental
- Price
- SAGE $5.00
- ESPR $2.46
- Analyst Decision
- SAGE Hold
- ESPR Buy
- Analyst Count
- SAGE 20
- ESPR 3
- Target Price
- SAGE $12.89
- ESPR $8.17
- AVG Volume (30 Days)
- SAGE 854.9K
- ESPR 5.0M
- Earning Date
- SAGE 10-29-2024
- ESPR 11-07-2024
- Dividend Yield
- SAGE N/A
- ESPR N/A
- EPS Growth
- SAGE N/A
- ESPR N/A
- EPS
- SAGE N/A
- ESPR N/A
- Revenue
- SAGE $106,399,000.00
- ESPR $295,451,000.00
- Revenue This Year
- SAGE N/A
- ESPR $198.22
- Revenue Next Year
- SAGE $118.26
- ESPR $25.83
- P/E Ratio
- SAGE N/A
- ESPR N/A
- Revenue Growth
- SAGE 837.60
- ESPR 187.12
- 52 Week Low
- SAGE $4.62
- ESPR $1.16
- 52 Week High
- SAGE $28.26
- ESPR $3.40
- Technical
- Relative Strength Index (RSI)
- SAGE 32.20
- ESPR 60.10
- Support Level
- SAGE $4.62
- ESPR $2.02
- Resistance Level
- SAGE $5.87
- ESPR $2.60
- Average True Range (ATR)
- SAGE 0.39
- ESPR 0.18
- MACD
- SAGE -0.10
- ESPR 0.01
- Stochastic Oscillator
- SAGE 21.18
- ESPR 72.60
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.